The Effect of Probiotic Combination on Helicobacter Pylori Infection in Children

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-31

Study Completion Date

2017-08-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The combination of two Lactubacillus reuteri strains, ATC 55730 and ATCC PTA 6457 are marketed as GASTRUS® and has been proposed as better option in increasing Helicobacter pylori eradication rate compared to the single strain ATC 55730, due to additional anti-inflammatory properties of the second strain.

Objectives of the study are to determine whether adding probiotic combination (GASTRUS®) to an anti- Helicobacter pylori regimen decreases adverse events and increases the eradication rate of Helicobacter pylori in the pediatric population infected with Helicobacter pylori bacteria.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lactobacillus Reuteri Strain Combination in Children Treated With PPI

NCT05484128

Gastric Lesion Proton Pump Inhibitor Adverse Reaction Probiotic

RECRUITING NA

Lactobacillus Reuteri ProGastria in Helicobacter Pylori-infected Adult Subjects on Proton Pump Inhibitors

NCT01456728

Helicobacter Pylori Infection

COMPLETED PHASE3

Effect of Probiotics on Gut Microbiota During the Helicobacter Pylori Eradication

NCT05662514

Helicobacter Pylori Infection Gut Microbiota

UNKNOWN NA

LGG for Prevention of Infectious Complications During PPI Treatment in Children

NCT01782118

Gastroesophageal Reflux Disease Gastrointestinal Infections Respiratory Tract Infections

UNKNOWN PHASE4

Efficacy of Two Probiotic Preparations in Children With Acute Diarrhoea

NCT02080130

Gastroenteritis

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a 10 week, randomized, double blind, placebo controlled, multicenter study to evaluate the efficacy of GASTRUS® on the frequency of adverse events and eradication rate of H. pylori infection in children.

Subjects: Children aged 5 (\>15 kg) -18 years, diagnosed with H. pylori infection during upper endoscopy with at least two validated tests, who meet all inclusion and exclusion criteria listed below. Subjects who are RUT (Rapid Urease Test) positive on the day of endoscopy will be offered to participate in the study, which includes 3 visits. They will be given information about the study and a 1-week diary to be filled out before visit 1. The properly filled diary will be considered as the screening tool to include the patients into the study and will be also considered as part of the study. At visit 1 written informed consent must be obtained from the caregivers and also from participants above 10 years of age. At each visit, physical examination will be performed as well as symptom assessment and diary evaluation. Only patients who have a positive culture for H. pylori and antibiotic susceptibility testing with no double resistance, and have filled in the diary will be enrolled. Patients will receive a prescription for triple therapy: omeprazole, amoxicillin and metronidazole / clarithromycin for 14 days depending on the antibiotic susceptibility. The dose regimens will be determined according to the weight of the child. The children will be randomized to receive chewable tablets containing 4x108 CFU of GASTRUS® or placebo of similar appearance and taste. Active and placebo tablets will be supplied. Subjects will take 1 tablet twice a day for 21 days. Diary 2 - will be dispensed (with instructions) and filled for 21 days until visit 2. Visit 2 will take place 21+/- 3 days after visit 1. At this visit a physical exam will be performed and diary 2 will be collected. Diary 3 will be reminded to be filled out one week before visit 3 which will be planned 8 weeks after visit 2 +/- 5 days. At visit 3, diary 3 will be collected. 13C-urea breath test or monoclonal stool antigen test will be performed to assess the H. pylori status after eradication treatment. In order to ensure that the children will fill their diaries, the parents will be phoned one week before visit 2 and 3.

Our study population will be children from all over Europe and Israel diagnosed with H. pylori infection with at least two recommended diagnostic methods. The investigators will complete documents considered for enrolment.

The sample size was calculated assuming that adverse effects will develop in 30% of treated children, aiming to detect difference of 20% based on a 0.80 power to detect statistically significant difference; therefore the recruitment will continue until 118 subjects are randomized into the 2 groups (test and placebo) of at least 59 children each. The estimated time to finish the study is 2-3 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Helicobacter Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Probiotic

Children in probiotic group will receive chewable tablets containing 4x108 CFU of Gastrus. Subjects will take 1 tablet twice a day for 21 days

Group Type ACTIVE_COMPARATOR

Gastrus

Intervention Type DIETARY_SUPPLEMENT

to compare Gastrus 4x108 tbl twice a day to placebo tbl

Placebo

Children in placebo group will receive placebo tablets of similar appearance and taste as Gastrus tablets. Subjects will take 1 placebo tablet twice a day for 21 days

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

to compare Gastrus 4x108 tbl twice a day to placebo tbl

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gastrus

to compare Gastrus 4x108 tbl twice a day to placebo tbl

Intervention Type DIETARY_SUPPLEMENT

Placebo

to compare Gastrus 4x108 tbl twice a day to placebo tbl

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lactobacillus reuteri (ATC 55730 and ATCC PTA 6457) Placebo pills

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Either sex age between 5 (\>15 kg) - 18 years.
2. Confirmed H. pylori infection (two out of four invasive methods positive (rapid urease test/histology/culture/PCR test) with positive culture and susceptibility testing for clarithromycin and metronidazole).
3. Able to be informed (patient/parents) of the nature of the study and willing to give written informed consent (consent from the parents must be obtained before any study-related procedures are conducted and assent of the child if older than 10 years).
4. Treatment naive children with H. pylori infection.

Exclusion Criteria

1. Significant acute or chronic GE disease (IBD, symptomatic coeliac disease…)
2. Known allergies to used antibiotics, proton pump inhibitors or probiotics
3. Having received treatment with antibiotics or bismuth compounds during the previous 30 days before endoscopy.
4. Having received proton pump inhibitors during the previous two weeks.
5. Having received probiotic therapy during the previous 14 days.
6. Being infected with a strain resistant to clarithromycin and metronidazole (double resistant)
7. Severe acquired or primary immunodeficiency.
8. Children with gastric or duodenal peptic ulcer disease

Minimum Eligible Age

5 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No